ATC Group: R06AE09 Levocetirizine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of R06AE09 in the ATC hierarchy

Level	Code	Title
`1`	R	Respiratory system
`2`	R06	Antihistamines for systemic use
`3`	R06A	Antihistamines for systemic use
`4`	R06AE	Piperazine derivatives
`5`	R06AE09	Levocetirizine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Code	Route	Amount	Notes
ORAL	Oral	5 mg

Active ingredients in R06AE09

Active Ingredient
Levocetirizine
Levocetirizine, the ® enantiomer of cetirizine, is a potent and selective antagonist of peripheral H₁-receptors. Pharmacodynamic studies in healthy volunteers demonstrate that, at half the dose, levocetirizine has comparable activity to cetirizine, both in the skin and in the nose.

Related product monographs

Document	Type	Information Source
CETIZAL Film-coated tablet	MPI, Generic	Health Products Regulatory Authority (ZA)
MUNTEL Film-coated tablet	MPI, EU: SmPC	Health Products Regulatory Authority (IE)
RINOZAL Film-coated tablet	MPI, EU: SmPC	Health Products Regulatory Authority (IE)
TEXAMER Film-coated tablet	MPI, Generic	Health Products Regulatory Authority (ZA)
XYZAL Oral solution	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)
ZOBRAL Film-coated tablet	MPI, EU: SmPC	Υπουργείο Υγείας (CY)